

UDS

, sarcoidosis, HIV

30

46±

14, 19, 11 (Table 1).

Magnetom Vision spinal 1.5T (Tesla) MRI

Jupiter 8000 Basic (WIEST, Unterhaching, Germany)

UDS 4

(Table 2).

5~20 ml/min

1998 1 2001 12

Table 2. Voiding difficulty score

- 3: Unable to micturate voluntarily
- 2: Marked difficulty in micturition
- 1: Mild to moderate difficulty in micturition
- 0: Normal micturition

level 7

가 (sensory

Table 1. Summary of clinical feature, UDS type and MRI finding

ID	Sex	Age	LMS	VDS	Sensory level	UDS type	MRI finding
1	Male	29	Mild	1	T4	Normal	C2
2	Male	54	Mild	1	T3	DH	C3~7
3	Female	73	Mild	1	C8	DH	C5~7
4	Male	50	Mild	2	L1	DA	T2
5	Male	38	Mild	2	T6	DA	T2
6	Male	44	Mild	2	T5	DH	T2, T5
7	Male	19	Mild	2	T8	DA	T3
8	Male	49	Mild	1	T10	DA	T3, T4
9	Male	30	Moderate	1	T10	Normal	T3, T8~9
10	Female	50	Mild	3	T4	DH	T3~4
11	Male	42	Mild	1	T5	DSD	T3~4
12	Female	69	Mild	2	T10	DA	T4~12
13	Male	43	Mild	2	T10	DA	T5~6
14	Male	39	Mild	2	T9	DA	T5~7
15	Male	30	Mild	2	T9	DH	T5~8
16	Male	43	Mild	1	T9	DA	T6, T7
17	Male	37	Mild	2	T10	DSD	T8~10
18	Male	37	Mild	1	T11	Normal	T9
19	Female	61	Mild	2	T10	DH	T10
20	Female	63	Mild	3	L4	DA	T11~12
21	Female	59	Mild	2	L1	DH	T11~12
22	Male	54	Mild	2	L1	DA	T11~12, L1
23	Female	13	Mild	2	L1	Normal	T12
24	Female	64	Mild	1	L1	DA	T12, L1
25	Female	68	Mild	3	L4	DA	L3
26	Female	55	Mild	3	S3	DA	S1~3
27	Male	37	Mild	2	T12	DH	Normal
28	Male	48	Mild	1	T11	Normal	Normal
29	Female	53	Severe	2	T10	DA	Normal
30	Male	37	Mild	1	T4	Normal	Normal

VDS; Voiding Difficulty Score (0; normal, 1; mild to moderate difficulty, 2; marked difficulty, 3; unable to micturation), Lt L/Ex; left lower extremity, Rt L/Ex; right lower extremity, LMS; lower extremities motor score (severe; grade 0-1, moderate; grade 2-3, mild; grade 4-5-), DA; detrusor areflexia, DH; detrusor hyperreflexia, DSD; detrusor sphincter dyssynergia




Figure 1. Cystometry finding of neurogenic bladder in detrusor hyperreflexia.




Figure 2. Cystometry finding of neurogenic bladder in detrusor areflexia.




Figure 3. Cystometry finding of neurogenic bladder in detrusor-sphincter dyssynergia.

3
cmH₂O
DH (Fig. 1),
(Fig. 2),
(Fig. 3) . UDS

15
DA
DSD
30
24
DA, 8 DH DSD
(Table 3).
MRI
26
4 MRI
9 가 DA 7
DH 2 DSD, 4
UDS
4 가 DA MRI 4
2 2 DA DH
(Table 3). UDS

(T10~L1) (S2~4)

Table 3. Summary of correlation between UDS type and lesion

	Cervicothoracic		Lumbosacral		Normal(%)	Total(%)
	Cervical(%)	Thoracic(%)	Lumbar(%)	Sacral(%)		
DA	0	9(41)	3(75)	1(25)	1(25)	14(47)
DH	2(9)	5(23)	0	0	1(25)	8(27)
DSD	0	2(9)	0	0	0	2(6)
Normal	1(5)	3(13)	0	0	2(50)	6(20)
Total	22(100)		4(100)		4(100)	30(100)

DA; detrusor areflexia, DH; detrusor hyperreflexia, DSD; detrusor sphincter dyssynergia, *P*-value: 0.416; statistically non-significant.

(S2~4)

가

UDS

DH가

19

가

UDS

가 UDS

DSD가

6-9

10 DA

25% DH, 75%

11가 , 100% DA

12 DSD

13 DA가 47% , 20%, DH가 27%,

DSD 6% DA가 66%

가 UDS

DH DA

UDS

DA 가

DSD가

DA가

UDS

DA

UDS

가

가 UDS

14 DSD UDS

가 , DH 33~55% DA

가 15-17 UDS

UDS

가 UDS

13,18

가

UDS

UDS

가 UDS가

UDS

UDS , DH

REFERENCES

1. Andersen O. Myelitis. *Curr Opin Neurol* 2000;13:311-316.
2. Scotti G, Gerevini S. Diagnosis and differential diagnosis of acute transverse myelopathy. The role of neuroradiological investigations and review of the literature. *Neurol Sci* 2001;22:69-73.
3. Ropper AH, Poskanzer DC. The prognosis of acute and subacute transverse myelopathy based on early signs and symptoms. *Ann Neurol* 1978;4:51-59.
4. Christensen PB, Wermuth L, Hinge HH, Bomers K. Clinical course and long-term prognosis of acute transverse myelopathy. *Acta Neurol Scand* 1990;81:431-435.
5. Burns AS, Rivas DA, Ditunno JF. The management of neurogenic bladder and sexual dysfunction after spinal cord injury. *Spine* 2001;26:129-136.
6. Blok BF. Central pathways controlling micturition and urinary continence. *Urology* 2002;59:13-17.
7. Blaivas JG, Barbalias GA. Detrusor-external sphincter dyssynergia in men with multiple sclerosis: an ominous urologic condition. *J Urol* 1984;131:91-94.
8. Fernandez O. Mechanisms and current treatments of urogenital dysfunction in multiple sclerosis. *J Neurol* 2002; 249:1-8.
9. Fowler CJ. Bladder afferents and their role in the overactive bladder. *Urology* 2002;59:37-42.
10. Pradhan S, Gupta RK, Kapoor R, Shashank S, Kathuria MK. Parainfectious conus myelitis. *J Neurol Sci* 1998; 161:156-162.
11. Berger Y, Blaivas JG, Oliver L. Urinary dysfunction in transverse myelitis. *J Urol* 1990;144:103-105.
12. Sakakibara R, Hittori T, Yasuda K. Micturition disturbance in acute transverse myelitis. *Spinal Cord* 1996;34: 481-485.
13. Kalita J, Shah S, Kapoor R, Misra UK. Bladder dysfunction in acute transverse myelitis: magnetic resonance imaging and neurophysiological and urodynamic correlations. *J Neurol Neurosurg Psychiatry* 2002;73:154-159.
14. Ciancio SJ, Mutchnik SE, Rivera VM, Boone TB. Urodynamic pattern changes in multiple sclerosis. *Urology* 2001;57:239-245.

-
15. Schoenberg HW, Gutrich JM. Management of vesical dysfunction in multiple sclerosis. *Urology* 1980;16:444-447.
 16. Goldstein I, Siroky MB, Sax DS, Krane RJ. Neurourologic abnormalities in multiple sclerosis. *J Urol* 1982;128:541-545.
 17. Wheeler JS Jr, Siroky MB, Pavlakis AJ, Goldstein I, Krane RJ. The changing neurourologic pattern of multiple sclerosis. *J Urol* 1983;130:1123-1126.
 18. Betts CD, D Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 1993;56:245-250.
 19. Blaivas JG. Management of bladder dysfunction in multiple sclerosis. *Neurology* 1980;30:12-18.